

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application of:	)	
	)	
Albrecht Groner et al	)	Group Art Unit: TBA
	)	
Serial No. TBA	)	Examiner: TBA
	)	
Filed: September 26, 2003	)	
	)	
For: ANIMAL CELLS AND PROCESSES FOR THE	)	Attorney Docket: 1280.106
REPLICATION OF INFLUENZA VIRUSES	)	

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

Applicants submit herewith this Information Disclosure Statement and Form PTO 1449. Copies of the each reference are not submitted herewith but may be found in parent application serial no. 10/194,784. Each reference was cited either by the applicant or the U.S. Patent Office. Accordingly, Applicants respectfully request that the Examiner consider and enter these documents into the file of the above-identified application. No fee is believe to be due; however, if any fee is necessary, please charge our Deposit Account No. 19-0733.

Respectfully submitted,

BANNER & WITCOFF, LTD.

By:



Michelle Holmes-Son  
Registration No. 47,660

1001 G Street, N.W., 11<sup>th</sup> Floor  
Washington, D.C. 20001-4597  
(202) 824-3000  
Dated: September 26, 2003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	4
-------	---	----	---

**C mplete if Known**

Application Number	TBA
Filing Date	September 26, 2003
First Named Inventor	Albrecht Groner et al
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	1280.106/002441.00067

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		WO 97/11093	3-27-1997	Cates et al		
		EP 0 389 925	12-27-1995	Murphy		
		WO 97/37000	10-09-1997	Groner et al		
		EP 00/19218	11/26/1980	Brown et al		
		WO 91/09937	07/11/1991	Mundt et al		
		WO 96/15231	05/23/1996	Barrett et al		
		WO 96/15232	05/23/1996	Kaverin et al		
		WO 97/37001	10/09/1997	Groner		
		GB 1,070,764	06/21/1965	Norden Lab		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

4

**Complete if Known**

Application Number

TBA

Filing Date

September 26, 2003

First Named Inventor

Albrecht Groner

Group Art Unit

TBA

Examiner Name

TBA

Attorney Docket Number

1280.106/002441.00067

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		YAMAOKA et al, Arch Virol (1995) 140: 937-944	
		FIELDS et al, Eds., Fields Virology, Second Edition, Raven Press, New York, New York (1990) 1:1092-1093	
		BROWN et al, Eds., Inactivated Influenza Vaccines Prepared in Cell Culture, Developments in Biological Standardization, S. Karger AG, Basel, Switzerland (1999) 98:13-21	
		JENNINGS et al, Vaccine, (1984) 2:75-80	
		GOVORKOVA et al, JID (1995) 172:250-3	
		Bulletin of the World Health Organization (1995) 73:431-435	
		ROBERTSON et al, Vaccine (1995) 13:1583-1588	
		Derwent Biotechnology Abstracts Accession No. 84-06431, HEESE (1984) Patent No. DE 3237313 (English Language Abstract) (full German text patent attached)	
		GOVORKOVA et al, J. Virol (1996) 70(8):5519-5524	
		BACHMAYER, Intervirology, (1975) 5:260-272	
		PALACHE et al, JID (1997) 176 (Suppl. 1): S20-23	
		BRANDS et al, Proceedings of the third International Conference on Options for the Control of Influenza, Options for the Control of Influenza III, Brown et al, Editors. Elsevier Science B.V., Amsterdam (1996), 683-693	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 4

**Complete if Known**

Application Number	TBA
Filing Date	September 26, 2003
First Named Inventor	Albrecht Groner
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	1280.106/002441.00067

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BRUMBACK, B. G. et al, "Rapid culture for influenza virus, types A and B, in 96-well plates", Clinical and Diagnostic Virology, 1995, 4:251-256	
		FRANK, A.L. et al, "Comparison of different tissue cultures for isolation and quantitation of influenza and parainfluenza viruses", Jrl of Clinical Microbiology, 1979, 10(1):32-36	
		MANCINI, "Evaluation of the "in vitro" multiplication of influenza virus and the enzymatic influence on viral growth", Revista de Farmacia e Bioquímica da Universidade de Sao Paulo, 1993, 29(2): 89-95, English Abstract provided	
		ORLICK M., et al, Structural variation occurring in the hemagglutinin of influenza virus A/Turkey/Oregon/71 during adaptation to different cell types", Virology, 1990, 176:531-538	
		PRIDGEN, C.L., "Influenza virus RNAs in the cytoplasm of chicken embryo cells treated with 3'deoxyadenosine", Jrl. of Virology, 1976, 18(1):356-360	
		LELAND, D.S. et al, E.H. Lennette, ed., Laboratory Diagnosis of Viral Infections, 2 <sup>nd</sup> Edition, 1992, pp. 19-20 and 526-527	
		TANNOCK et al, Evaluation of chicken kidney and chicken embryo kidney cultures for the large-scale growth of attenuated influenza virus master strain", Vaccine, 1985, 3(3):333-9, Database Dialog #05806807	
		KILBOURNE, E.D., Influenza, 1987, Plenum Medical Book, 89-110	
		KLENK et al, Activation of Influenza A Viruses by Trypsin Treatment", Virology, 1975, 68, 426-439	
		LAZAROWITZ et al, "Enhancement of the Infectivity of Influenza A and B Viruses by Proteolytic Cleavage of the Hemmagglutinin Polypeptide", Virology, 1975, 68:440-454	
		MERTEN et al, "Production of Influenza Virus in Cell Cultures for Vaccine Preparation", Advances in Experimental Medicine and Biology, 1996, 297:141-151	
		TOBITA et al, "Plaque Assay and Primary Isolation of Influenza A Viruses in an Established Line of Canine Kidney Cells (MDCK) in the Presence of Trypsin", Med. Microbiol. Immunol., 1975, 162:9-14	
		PERRIN et al, An Experimental Rabies Vaccine Produced with a New BHK-21 Suspension Cell Culture Process: Use of Serum Free Medium and Perfusion - Reactor System", Vaccine 1995 13(13):1244-1250	

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

4

**Complete if Known**

Application Number

TBA

Filing Date

September 26, 2002

First Named Inventor

Albrecht Groner

Group Art Unit

TBA

Examiner Name

TBA

Attorney Docket Number

1280.106/002441.00067

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		HOUGLAND et al, Growth 42(2) 1790188, 1978 (Abstract Only)	
		RODRIGUEZ-BOULAN et al, Journal of Cell Biology, 96:866-874, 1983	
		ALONSO-CAPLEN et al, Journal of Cell Biology, 97:659-668, 1983	
		Mancini et al, Revista de Farmacia e Bioquimica da Universidade de Sao Paulo, 1993, 29(2), 89-95	
		Skibbens et al, J. Cell Biol. (1989) 108:821-832	

Examiner  
Signature

Date

Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.